(S)-1-(4-((5-Cyclopropyl-1H-Pyrazol-3-Yl)Amino)Pyrrolo[2,1-F][1,2,4]Triazin-2-Yl)-N-(6-Fluoropyridin-3-Yl)-2-Methylpyrrolidine-2-Carboxamide (S)-1-(4-((5-环丙基-1H-吡唑-3-基)氨基)吡咯[2,1-f][1,2,4]三嗪-2-基)-N-(6-氟吡啶-3-基)-2-甲基吡咯烷-2-甲酰胺
CAS 1001350-96-4 MFCD18633202
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
产品应用
- BMS-754807 is an orally bioavailable antagonist of human insulin-like growth factor type I receptor (IGF-1R) with potential antineoplastic activity. IGF-1R antagonist BMS-7548077 binds to IGF-1R, preventing IGF-1 ligand binding and activation of IGF-1R-mediated signaling pathways; inhibition of IGF-1R-mediated signaling pathways may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R is a receptor tyrosine kinase expressed on most tumor cells and is involved in mitogenesis, angiogenesis, and tumor cell survival.